Bio-Path outlines obesity program for BP1001-A; discontinues BP1002 Phase 1 trial

BIO-PATH HOLDINGS, INC.

BP1001-A aims to treat obesity in Type 2 diabetes by downregulating Grb2 to enhance insulin signaling.
IND-enabling testing for BP1001-A expected in Q4 2024; preclinical studies ongoing.
Discontinues Phase 1 study of BP1002 for lymphoma/CLL due to enrollment challenges.
Company reallocates resources to metabolic program from oncology pipeline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.